Bladder cancer (BC) is the most frequent cancer affecting the urinary tract. With the growing era of targeted therapies around the 2000s, many trials evaluated the efficacy of targeted therapy in advanced BC. However, no approval was given yet to any form of targeted therapy when it comes to BC. The aim of this paper was to report the most pivotal trials that evaluated different families of targeted therapy in the treatment of BC, according to their biomarkers (FGFR3, EGFR, HER2, VEGF and PI3K/AKT/mTOR). The ongoing trials testing targeted therapies in advanced BC were then summarized. Finally, the different immunotherapies approved for this disease and their potential combination with targeted therapy were addressed.
Future oncology (London, England). 2019 Apr 12 [Epub ahead of print]
Joya-Rita Hindy, Tarek Souaid, Hampig Raphael Kourie, Joseph Kattan
Medical Genetics Unit, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon., Department of Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.